AC-264613

Research use only, not for human use.

AC-264613 is an agonist of the GPCR protease-activated receptor 2 (PAR2).

AC-264613 is the first agonist of the G-protein-coupled receptor (GPCR) protease activated receptor 2 (PAR2). AC-264613 suppresses interferon regulatory factor 5 and decreases interleukin-12p40 production by lipopolysaccharide-stimulated macrophages. AC-264613 activated PAR2 signaling in cellular proliferation assays, phosphatidylinositol hydrolysis assays, and Ca(2+) mobilization assays, with potencies ranging from 30 to 100 nM.

AC-264613 (10 μM; for 6 hours) causes a decrease of IRF5 expression and also significantly reduces p53 protein expression in macrophages. Western Blot Analysis Cell Line:Granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent macrophages Concentration:10 μM Incubation Time:6 hours Result:Significantly decreased IRF5 expression and reduced p53 protein levels.

AC-264613 exhibits moderate elimination half-live (T1/2=2.5±2.0 h) following i.p. administration (10 mg/kg) in male Sprague-Dawley rats.

AC-264613 | AC 264613 | AC264613

Others

Other Targets

PAR-2

——

——

1051487-82-1

400.28

C19H18BrN3O2

>98% (HPLC)

——

O=C([C@H]1C(=O)NC[C@@H]1c1ccccc1)N/N=C(/c1cccc(Br)c1)\C

(3R,?4S)?-?rel-2-?Oxo-?4-?phenyl-?3-?pyrrolidinecarboxyli?c acid 2-?[1-?(3-?bromophenyl)?ethylidene]?hydrazide

(-20℃)

With Ice Pack

≥ 2 years